Stereotaxis (STXS) AI Stock Analysis

• Market Cap: $193.50M
• Dividend Yield: N/A
• Average Volume (3M): 257.53K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.80
• Revenue Growth: 1.50%
• EPS Growth: -20.00%
• Country: US
• Employees: 139
• Sector: Healthcare
• Sector Strength: 37
• Industry: Medical - Instruments & Supplies
• EPS (TTM): -0.07
• Shares Outstanding: 86,000,850
• 10 Day Avg. Volume: 221,061
• 30 Day Avg. Volume: 257,534
• PEG Ratio: 2.25
• Price to Book (P/B): 69.18
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -24.51
• Enterprise Value/Market Cap: 0.98
• Enterprise Value/Revenue: 1.84
• Enterprise Value/Gross Profit: 12.97
• Enterprise Value/Ebitda: -2.08
• 1Y Price Target: $4.67
• Price Target Upside: 105.73% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3

• Rating: 63 Neutral
• Price Target: $2.50 ▲(10.13%Upside)

Stereotaxis shows potential with strong revenue growth and product launches but faces significant profitability challenges. The technical analysis indicates a slight positive momentum, but valuation remains weak due to negative earnings. Overall, the score reflects a balanced outlook with notable risks and opportunities.

Positive Factors

Clinical Performance

Initial peer-reviewed results for Stereotaxis’ MAGiC catheter show 94% acute efficacy and strong safety across a broad range of arrhythmias.

Revenue Growth

STXS posted 1Q revenue of $7.5M, beating the Street's $6.9M estimate by a comfortable margin.

Strategic Partnerships

STXS’s acceptance into the NVIDIA Connect program marks a pivotal milestone in its long-term innovation strategy, enabling future advanced AI integration to enhance robotic precision, automation, and decision support.

Negative Factors

Cash Management

Free cash flow was positive in the quarter, at $1.3M, with no debt on the balance sheet, but ongoing management of cash resources remains critical.

Financial Performance

The 4Q operating loss was $7.6M, while the net loss was $7.5M.

Stereotaxis Business Overview & Revenue Model

Company Description

Stereotaxis (STXS) is a medical technology company that specializes in innovative robotic systems designed to enhance the treatment of arrhythmias and other cardiovascular conditions. The company operates primarily within the healthcare sector, focusing on the development and commercialization of its advanced robotic magnetic navigation systems, including the Niobe and Genesis systems, which allow for precise and minimally invasive surgical interventions in cardiac procedures.

How the Company Makes Money

Stereotaxis generates revenue primarily through the sale of its robotic systems and related products. This includes the initial sale of the robotic navigation systems, as well as recurring revenue from the sale of disposable components and service agreements. The company also earns income through partnerships with hospitals and medical centers, providing them with the necessary technology and support for advanced cardiac procedures. Additionally, Stereotaxis may earn from training and support services offered to healthcare providers to ensure effective use of their systems.

Stereotaxis Financial Statement Overview

Summary

Stereotaxis has a strong gross profit margin, but its high operational costs result in negative net income, leading to concerns about profitability. The balance sheet shows balanced leverage but limited equity, and cash flow challenges highlight the need for strategic cash management.

Income Statement

Stereotaxis has shown marginal revenue growth over the years but faces challenges in profitability. The gross profit margin remains robust at around 54.2% for 2024, but the company continues to operate at a net loss, with a net profit margin of -94.2% in 2024. This indicates high operational costs relative to revenue, leading to negative EBIT and EBITDA margins, which suggest a need for cost management and strategic improvements.

Balance Sheet

The debt-to-equity ratio for 2024 stands at approximately 0.99, showing a balanced leverage profile. However, the equity ratio is relatively low at 13.0%, indicating limited asset backing by equity. The company’s return on equity is negative due to sustained losses, highlighting potential financial stability concerns.

Cash Flow

Free cash flow has seen a slight improvement but remains negative, reflecting cash outflow challenges. The operating cash flow to net income ratio is unfavorable due to negative cash flows, indicating issues in converting revenue into cash. The free cash flow to net income ratio also highlights cash generation difficulties, requiring strategic cash flow management.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	27.51M	26.92M	26.77M	28.15M	35.02M	26.63M
Gross Profit	14.69M	14.59M	14.86M	18.47M	23.23M	18.97M
EBITDA	-24.98M	-23.77M	-21.24M	-18.35M	-12.78M	-6.59M
Net Income	-25.68M	-24.05M	-20.71M	-18.29M	-8.44M	-6.65M
Balance Sheet
Total Assets	45.70M	46.72M	41.91M	53.41M	60.98M	55.46M
Cash, Cash Equivalents and Short-Term Investments	10.60M	12.22M	19.82M	28.43M	38.74M	43.94M
Total Debt	5.87M	6.01M	5.49M	5.86M	6.11M	4.45M
Total Liabilities	37.53M	35.29M	19.99M	21.48M	21.56M	15.23M
Stockholders Equity	2.88M	11.43M	21.92M	31.93M	39.42M	40.23M
Cash Flow
Free Cash Flow	-7.96M	-8.53M	-9.51M	-10.79M	-4.34M	-3.58M
Operating Cash Flow	-7.93M	-8.50M	-9.14M	-8.41M	-2.95M	-3.51M
Investing Cash Flow	74.00K	74.00K	19.77M	-22.09M	-1.40M	-70.90K
Financing Cash Flow	299.00K	297.00K	81.00K	220.00K	547.41K	17.34M

Stereotaxis Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2.27
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For STXS, the sentiment is Positive. The current price of 2.27 is above the 20-day moving average (MA) of 2.19, above the 50-day MA of 2.15, and above the 200-day MA of 2.09, indicating a bullish trend. The MACD of 0.02 indicates Negative momentum. The RSI at 56.62 is Neutral, neither overbought nor oversold. The STOCH value of 70.95 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for STXS.

Stereotaxis Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ATR	76 Outperform	$10.43B	28.87	15.15%	1.14%	0.34%	17.27%
HOLX	70 Outperform	$14.65B	27.75	11.77%	―	1.66%	21.95%
MMSI	70 Outperform	$5.53B	45.85	9.16%	―	8.24%	18.54%
STXS	63 Neutral	$193.50M	―	-179.82%	―	1.50%	-20.00%
ATRC	60 Neutral	$1.52B	―	-8.38%	―	15.79%	-1.20%
STAA	57 Neutral	$860.76M	55.81	-19.14%	―	-14.44%	-557.38%
Sector *	52 Neutral	$7.52B	0.21	-63.76%	2.30%	16.15%	0.89%

Stereotaxis Corporate Events

Stereotaxis Holds 2025 Annual Shareholders Meeting

On May 15, 2025, Stereotaxis held its Annual Meeting of Shareholders, where a 59% quorum was achieved with 63,792,419 shares represented. During the meeting, shareholders elected two Class III directors to serve until the 2028 Annual Meeting and ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for fiscal year 2025. The election of directors was determined by a plurality of votes, and the proposal to ratify the accounting firm was passed by a majority of the outstanding shares.

The most recent analyst rating on (STXS) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Stereotaxis stock, see the STXS Stock Forecast page.